%0 Journal Article
%A Smith-Byrne, Karl
%A Cerani, Agustin
%A Guida, Florence
%A Zhou, Sirui
%A Agudo, Antonio
%A Aleksandrova, Krasimira
%A Barricarte, Aurelio
%A Rodríguez-Barranco, Miguel
%A Borchers, Christoph H
%A Gram, Inger T
%A Han, Jun
%A Amos, Christopher I
%A Hung, Rayjean J
%A Grankvist, Kjell
%A Nøst, Therese H
%A Imaz, Liher
%A Chirlaque-López, María Dolores
%A Johansson, Mikael
%A Kaaks, Rudolf
%A Kühn, Tilman
%A Martin, Richard M
%A McKay, James D
%A Pala, Valeria
%A Robbins, Hilary A
%A Sandanger, Torkjel M
%A Schibli, David
%A Schulze, Matthias B
%A Travis, Ruth C
%A Vineis, Paolo
%A Weiderpass, Elisabete
%A Brennan, Paul
%A Johansson, Mattias
%A Richards, J Brent
%T Circulating Isovalerylcarnitine and Lung Cancer Risk: Evidence from Mendelian Randomization and Pre-Diagnostic Blood Measurements.
%J Cancer epidemiology, biomarkers & prevention
%V 31
%N 10
%@ 1055-9965
%C Philadelphia, Pa.
%I AACR
%M DKFZ-2022-01496
%P 1966-1974
%D 2022
%Z  2022 Oct 4;31(10):1966-1974
%X Tobacco exposure causes 8 of 10 lung cancers, and identifying additional risk factors is challenging due to confounding introduced by smoking in traditional observational studies.We used Mendelian randomization (MR) to screen 207 metabolites for their role in lung cancer predisposition using independent genome-wide-association studies (GWAS) of blood metabolite levels (n =7,824) and lung cancer risk (n=29,266 cases / 56,450 controls). A nested case control study (656 cases and 1,309 matched controls) was subsequently performed using pre-diagnostic blood samples to validate MR association with lung cancer incidence data from population-based cohorts (EPIC and NSHDS).An MR-based scan of 207 circulating metabolites for lung cancer risk identified that blood isovalerylcarnitine (IVC) was associated with a decreased odds of lung cancer after accounting for multiple testing (Log10-OR = 0.43, 95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35839461
%R 10.1158/1055-9965.EPI-21-1033
%U https://inrepo02.dkfz.de/record/180700